Protara Therapeutics, Inc. (TARA)
NASDAQ:TARA
Want to see TARA full AI Analyst Report?
Top Page
Protara Therapeutics
(NASDAQ:TARA)
Select Model
Select Model
Rating:55Neutral
Price Target:
$5.00
▼(-8.09% Downside)
Action:Reiterated
Date:05/14/26
The score is primarily constrained by weak operating fundamentals—no revenue, continued losses, and negative cash flow with rising burn—despite a relatively strong, low-debt balance sheet. Technicals are slightly bearish/neutral. Offsetting these risks, recent corporate updates on TARA-002 were notably positive and provide a meaningful catalyst, but profitability and cash runway/dilution concerns keep the overall score moderate.
Positive Factors
Low leverage / strong balance sheet
Very low debt relative to equity gives Protara financial flexibility to fund clinical programs without large interest burdens, lowering insolvency risk. Material equity growth since 2023 indicates the company can access capital markets, supporting multi-quarter development timelines and strategic optionality.
Negative Factors
No revenue / recurring losses
Protara is still a research-driven, pre-commercial company with no product revenue, meaning operations cannot be self-funded. Persistent operating and net losses require continued financing, making long-term sustainability contingent on trial outcomes or regular capital raises rather than internal cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
Very low debt relative to equity gives Protara financial flexibility to fund clinical programs without large interest burdens, lowering insolvency risk. Material equity growth since 2023 indicates the company can access capital markets, supporting multi-quarter development timelines and strategic optionality.
Read all positive factors
Protara Therapeutics (TARA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$267.53M
Dividend YieldN/A
Average Volume (3M)730.08K
Price to Earnings (P/E)―
Beta (1Y)0.73
Revenue GrowthN/A
EPS Growth21.65%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.46
Shares Outstanding56,204,240
10 Day Avg. Volume963,228
30 Day Avg. Volume730,080
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.16
Price to Sales (P/S)0.00
P/FCF Ratio-4.04
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.91K
Enterprise Value/Ebitda-2.46
Forecast
1Y Price Target
$26.00Price Target Upside377.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.4
Revenue Forecast (FY)N/A
Protara Therapeutics Business Overview & Revenue Model
Company Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cel...
How the Company Makes Money
null...
Protara Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -90.00K | -362.00K | 0.00 | -341.00K | 0.00 | 0.00 |
| EBITDA | -69.69M | -64.19M | -48.82M | -43.27M | -64.57M | -45.40M |
| Net Income | -63.31M | -57.44M | -44.60M | -40.42M | -65.95M | -47.25M |
Balance Sheet | ||||||
| Total Assets | 191.92M | 209.47M | 181.45M | 78.95M | 113.29M | 172.60M |
| Cash, Cash Equivalents and Short-Term Investments | 135.79M | 155.55M | 170.29M | 65.58M | 84.37M | 91.23M |
| Total Debt | 3.06M | 3.36M | 4.48M | 5.47M | 6.38M | 7.24M |
| Total Liabilities | 10.71M | 13.06M | 14.32M | 10.63M | 11.21M | 10.68M |
| Stockholders Equity | 181.21M | 196.41M | 167.13M | 68.32M | 102.08M | 161.91M |
Cash Flow | ||||||
| Free Cash Flow | -63.05M | -56.46M | -35.87M | -37.60M | -26.58M | -35.10M |
| Operating Cash Flow | -62.99M | -56.37M | -35.81M | -37.56M | -26.46M | -34.50M |
| Investing Cash Flow | -95.86M | -139.49M | 19.16M | 53.11M | 14.95M | -98.19M |
| Financing Cash Flow | 82.13M | 82.72M | 139.87M | -91.00K | -90.00K | -228.00K |
Protara Therapeutics Technical Analysis
Negative
5.44
Price Trends
5.13
Negative
5.61
Negative
5.19
Negative
Market Momentum
-0.14
Positive
42.44
Neutral
46.46
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TARA, the sentiment is Negative. The current price of 5.44 is above the 20-day moving average (MA) of 5.09, above the 50-day MA of 5.13, and above the 200-day MA of 5.19, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 42.44 is Neutral, neither overbought nor oversold. The STOCH value of 46.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TARA.
Protara Therapeutics Risk Analysis
Protara Therapeutics disclosed 62 risk factors in its most recent earnings report. Protara Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Protara Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $170.81M | 10.94 | 28.10% | ― | 27.80% | 268.45% | |
55 Neutral | $267.53M | -3.21 | -38.70% | ― | ― | 21.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $151.56M | -4.56 | -153.99% | ― | ― | 94.79% | |
49 Neutral | $409.44M | -6.25 | -54.60% | ― | ― | -60.98% | |
41 Neutral | $29.12M | -0.59 | -217.27% | ― | ― | -74.39% | |
41 Neutral | $236.53M | -2.80 | -137.99% | ― | 1033.89% | 36.35% |
* Healthcare Sector Average
TARA
Protara Therapeutics
4.75
1.71
56.25%
PLX
Protalix
2.10
0.55
35.48%
HURA
TuHURA Biosciences
2.35
-0.71
-23.20%
SKYE
Skye Bioscience
0.85
-1.13
-57.12%
OBIO
Orchestra BioMed Holdings
3.98
1.13
39.65%
ZURA
Zura Bio
4.20
3.19
315.84%
Protara Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Protara Therapeutics Highlights Positive TARA-002 Phase 2 Results
Positive
Mar 30, 2026
On March 30, 2026, Protara Therapeutics reported updated data from its ongoing Phase 2 ADVANCED-2 trial of TARA-002 in Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, confirming a six-month complete response rate of ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.